Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : F. Hoffmann-La Roche Ltd
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to gemcitabine + platinum-based chemotherapy in previously untreated patients with metastatic, squamous, PD-L1-selected, non-small cell lung cancer
The primary objective for this study is to evaluate the efficacy of MPDL3280A compared with carboplatin or cisplatin + gemcitabine in chemotherapy-naive patients with Stage IV squamous NSCLC, as measu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an α4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate
1. To determine the efficacy of RO0506997 (a dual α4 integrin [VCAM1] antagonist) in combination with methotrexate, in adult patients with rheumatoid arthritis (RA) who currently exhibit a partial cli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Efficacy and Safety of RO4917523 as add-on therapy in patients with Major Depressive Disorder who have inadequate response to ongoing antidepressant medication
To evaluate the efficacy of two fixed doses of RO4917523 compared to placebo over 6 weeks as adjunctive therapy in patients with MDD with inadequate response to ongoing antidepressant treatment. The c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection
Interim analysis: - To assess the efficacy, in the IA population, of RO5217790 compared to placebo in achieving histologic resolution at Month 6 (determined by evaluation of tissue derived from surgic...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic RO5534262 versus No Prophylaxis in Hemophilia A Patients with Inhibitors Ensayo clínico Fase III para evaluar la Eficacia, Seguridad y Farmacocinética del RO5534262 profiláctico frente a la no profilaxis en pacientes con hemofilia A con inhibidores
To evaluate the efficacy of prophylactic RO5534262 compared with no prophylaxis in patients with hemophilia A with inhibitors Evaluar la eficacia de RO5534262 profiláctico en comparación con la ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection
To study the effects of dose and duration of the HCV polymerase inhibitor prodrug (RO5024048) in combination with PEG-IFN and RBV versus the currently approved combination of PEG-IFN and RBV (SOC) in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia
To document that RO0503821 administered for prolonged periods is efficacious, safe and well tolerated in patients treated for chronic renal anemia
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®
To determine reversibility of eGFRMDRD decrease following 52 weeks of 150 μg aleglitazar treatment and 8 weeks follow up observation after the last study medication, in patients with T2D and moderate ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC with Perjeta and Docetaxel in Patients with HER2-positive Advanced Breast Cancer
The primary objective for this study is to evaluate the safety and tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in patients with HER2−positive advanced (metastatic or loc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study Evaluating the Safety, Tolerability and Anti-tumor Activity of Polatuzumab Vedotin in Combination with Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
- Phase 1b: Safety and tolerability of the combination of polatuzumab vedotin with bendamustine and rituximab (BR) or bendamustine and obinutuzumab (BG) when administered to patients with relapsed or ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant